Sihuan Pharmaceutical Holdings Group Ltd. provided unaudited consolidated guidance for the six months ended 30 June 2023. For the period, the company expected to record a total revenue of not less than RMB 1 billion during the Period, representing a decrease of not more than 30% as compared to the same period in 2022, mainly due to the generic drug segment affected by the price reduction as a result of centralized procurement and the decline
in sales volume of certain products as a result of being newly included in the key monitoring catalogue.